Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients

Experimental and Clinical Cardiology

Volumn 13, Issue 1, 2008, Pages 19-24

  Haugen, Espen ^a   Gan, Li Ming ^b   Isic, Azra ^a   Skommevik, Tomas ^a   Fu, Michael ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokine; Elderly; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; ELDERLY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PROTEIN BLOOD LEVEL; STROKE;

EID: 41149116161     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002;91:988-98.
2. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
3. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989;169:823-32.
4. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J Clin Invest 1992;90:389-98.
5. Franco F, Thomas GD, Giroir BF, et al. Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 1999;99:448-54.
6. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
7. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9.
8. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95:3C-8C.
9. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6.
10. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7.
11. Deswal A, Bozkurt B, Sera Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
12. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30.
13. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
14. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
15. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000;15:264-72.
16. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005;26:65-9.
17. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001;103:2776-9.
18. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40.
19. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
20. Vázuqez-Oliva O, Fernández-Real JM, Zamora A, Vilaseca M, Badimón L. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects. J Hum Hypertens 2005; 19:457-62.
21. Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol 2007;171:315-25. (Erratum in 2007;171:1078).
22. Haugen E, Chen J, Wikström J, Grönros J, Gan LM, Fu LX. Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. Int J Cardiol 2007;115:24-8.
23. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006;108:346-53.
24. Liu T, Li G, Li L, Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: A meta-analysis. J Am Coll Cardiol 2007;49:1642-8.
25. Lee SH, Chen YC, Chen YJ, et al. Tumor necrosis factor-alpha alters calcium handling and increases arrhythmogenesis of pulmonary vein cardiomyocytes. Life Sci 2007;80:1806-15.